Follow-On Biologics Will Rely On “Case-By-Case” Approach – Rep. Waxman

FDA's development of a guidance for follow-on versions of insulin and human growth hormone will be a key milestone in demonstrating the agency's ability to implement a "case-by-case" approach to "generic" biologics, Rep. Henry Waxman (D-Calif.) said